Europe Over-the-Counter (OTC) Drugs Market – Size, Outlook, Trends and Forecast (2024 – 2032)

Over-the-counter(OTC) medicine is also known as OTC or nonprescription medicine. All these terms refer to that medicine because you can buy without a prescription. They are safe and effective when you follow the directions on the label and as directed by your healthcare professional.

Europe Over-the-Counter (OTC) Drugs Market Share:

Compared to the past years, Over-the-Counter devices have undergone a predominant change in the markets of Europe. The Product Type segment is expected to have the highest growth rate.

Europe Over-the-Counter (OTC) Drugs Market Size & Growth:

The European market for over-the-counter (OTC) drugs is estimated to be USD 32.8 billion in the year 2018 and is expected to reach USD 37.9 billion by the end of the year 2024. During this period, the market is expected to grow at a CAGR of 3.30%.

There is a wide range of Products in Over-the-Counter Drugs Market such as Cough and Cold, Vitamin, Minerals and Supplements, Analgesics, and Digestive Products. As there are enormous applications, the market size related to OTC is even more prominent in  Europe.

Product Innovation, Increasing distribution channels for OTC drugs, Pharmaceutical companies switching to OTC from Rx drugs, Ease in advertising restrictions for these OTC drugs are significant factors that propel or drive the growth of  Europe Over-the-Counter(OTC) Drugs market.

Europe Over-the-Counter (OTC) Drugs Market Industry Analysis:

The Europe Over-the-Counter Drugs market has been segmented by product type, which is sub-segmented into digestive products, vitamins, minerals and supplements, analgesics, cough and cold, and others.

Europe Over-the-Counter (OTC) Drugs Market Outlook:

Incorrect self-diagnosis and Concerns regarding the probability of substance abuse of OTC drugs are the two major factors responsible for the hampering of the OTC market growth.

Europe Over-the-Counter (OTC) Drugs Market Trends:

• Perrigo Company announced that it had received tentative approval from the U.S. Food and Drug Administration for the generic version of Prolensa 0.07%. Perrigo previously settled litigation with Bausch & Lomb Inc. for this product.
• Momenta Pharmaceuticals, Inc. and Mylan N.V. announced the development strategy for M710, a proposed biosimilar to EYLEA® injection. EYLEA is the market-leading vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of neovascular (wet) age-related macular degeneration, macular oedema following retinal vein occlusion, diabetic macular oedema and diabetic retinopathy in patients with diabetic macular oedema.

Europe Over-the-Counter (OTC) Drugs Market Research report includes:

• An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
• To have complete market analysis through industry value chain analysis, Porter’s five, PESTLE, SWOT analysis, and Y-o-Y analysis.
• Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year–On–Year
• Identifying DROC in the current market and their impact in altering the market dynamics.
• Competitive landscape analysis to identify the merger and acquisition which will have a comparative financial study with significant competitors.
• Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
• Identify the latest developments, market shares and strategies that are employed by the major market players, such as
• Mylan
• Galderma
• Perrigo UK
• Navamedic
• Medlite AS